4 studies found for:    18809613 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NYESO-1 Murine TCR-Gene Engineered Lymphocytes
Condition: Metastatic Cancers Other Than Melanoma That Express ESO Antigen
Interventions: Biological: Anti-NY ESO-1 mTCR PBL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Aldesleukin
2 Terminated Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
Conditions: Metastatic Cancer;   Metastatic Melanoma;   Metastatic Renal Cancer
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Other: IL-12 & amp; Anti-NY ESO1 TCR PBL
3 Recruiting Phase II Study of CD62L+-Derived T Lymphocytes Transduced With a T Cell Receptor Recognizing the NY-ESO-1 Antigen and Aldesleukin Following Lymphodepletion in Patients With NY-ESO-1 Expressing Melanoma
Conditions: Metastatic Cancer;   Metastatic Melanoma
Interventions: Biological: Anti-NY ESO-1 TCR CD62L+ cells;   Drug: aldesleukin;   Drug: cyclophosphamide;   Drug: fludarabine
4 Active, not recruiting Prospective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200 TBI
Conditions: Metastatic Melanoma;   Skin Cancer
Interventions: Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Young Tumor Infiltrating Lymphocytes;   Procedure: 1200 Gy Irradiation

Indicates status has not been verified in more than two years